Azaindazole compounds as CCR1 receptor antagonists

Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of...

Full description

Saved in:
Bibliographic Details
Main Authors Kuzmich, Daniel, Lord, John, Mao, Can
Format Patent
LanguageEnglish
Published 24.04.2012
Online AccessGet full text

Cover

More Information
Summary:Disclosed are compounds of the formula (I), useful for treating a variety of diseases and disorders that are mediated or sustained through the activity of CCR1 including autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Also disclosed are intermediates thereof, and methods of making and methods of using same.